Utilization of Halogen Bond in Lead Optimization: A Case Study of Rational Design of Potent Phosphodiesterase Type 5 (PDE5) Inhibitors
Journal of Medicinal Chemistry2011Vol. 54(15), pp. 5607–5611
Citations Over TimeTop 10% of 2011 papers
Zhijian Xu, Zheng Liu, Tong Chen, Tiantian Chen, Zhen Wang, Guanghui Tian, Jing Shi, Xuelan Wang, Yunxiang Lu, Xiuhua Yan, Guan Wang, Hualiang Jiang, Kaixian Chen, Shudong Wang, Yechun Xu, Jingshan Shen, Weiliang Zhu
Abstract
For proof-of-concept of halogen bonding in drug design, a series of halogenated compounds were designed based on a lead structure as new inhibitors of phosphodiesterase type 5. Bioassay results revealed a good correlation between the measured bioactivity and the calculated halogen bond energy. Our X-ray crystal structures verified the existence of the predicted halogen bonds, demonstrating that the halogen bond is an applicable tool in drug design and should be routinely considered in lead optimization.
Related Papers
- → Principles and Applications of Halogen Bonding in Medicinal Chemistry and Chemical Biology(2012)1,272 cited
- → Halogen bonding for rational drug design and new drug discovery(2012)311 cited
- → Halogens in Protein–Ligand Binding Mechanism: A Structural Perspective(2019)187 cited
- → Rediscovery of Halogen Bonds in Protein-Ligand Complexes(2010)36 cited
- → Halogen bonding interactions with the [Mo3S7Cl6]2− cluster anion in the mixed valence salt [EDT-TTFI2]4[Mo3S7Cl6]·CH3CN(2008)22 cited